0000899243-21-034137.txt : 20210825 0000899243-21-034137.hdr.sgml : 20210825 20210825160025 ACCESSION NUMBER: 0000899243-21-034137 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210617 FILED AS OF DATE: 20210825 DATE AS OF CHANGE: 20210825 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Angermayer Christian CENTRAL INDEX KEY: 0001845872 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40493 FILM NUMBER: 211206906 MAIL ADDRESS: STREET 1: BLOCK A, APT.12 STREET 2: IL-PIAZZETTA, TOWER ROAD CITY: SLIEMA STATE: O1 ZIP: SLM1605 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ATAI Life Sciences N.V. CENTRAL INDEX KEY: 0001840904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 VARICK STREET CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: (617) 699-5876 MAIL ADDRESS: STREET 1: 180 VARICK STREET CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: ATAI Life Sciences B.V. DATE OF NAME CHANGE: 20210115 3/A 1 doc3a.xml FORM 3/A SUBMISSION X0206 3/A 2021-06-17 2021-06-17 0 0001840904 ATAI Life Sciences N.V. ATAI 0001845872 Angermayer Christian 66 & 67, BEATRICE, AMERY STREET SLIEMA O1 SLM1707 MALTA 1 0 1 0 Common Shares 27805200 I By Apeiron Investment Group Ltd. Convertible Notes Common Shares 2367200 I By Apeiron Investment Group Ltd. The reporting person's original Form 3 and subsequently filed Form 4 inadvertently understated this amount by 8,320,000 shares. Apeiron Investment Group Ltd. is the co-managing member of Presight Capital Management I, LLC, which is the general partner of Presight II, L.P. Therefore, Apeiron Investment Group Ltd. may be deemed to share beneficial ownership of the Common Shares held by Presight II, L.P. Apeiron Investment Group Ltd. is owned and controlled by Christian Angermayer. Mr. Angermayer may be deemed to have beneficial ownership over the shares held by Apeiron Investment Group Ltd. and Presight II, L.P. The Convertible Notes are currently exercisable and will mature on September 30, 2025. The reporting person's original Form 3 inadvertently overstated this amount by 5,952,800 shares. The conversion price for the Convertible Notes is Euro 17.00 per share. /s/ Ryan Barrett, Attorney-in-fact 2021-08-25